“O.itemList.length” “- this.config.text.ariaShown
“This.config.text.ariaFermé”
By Alistair Smout and Josephine Mason
LONDON (Reuters) – Britain will buy COVID-19 vaccines from US drug brands Johnson and Johnson and Novavax Inc, corporations said Friday, bringing the total number of British government agreements to six as the injection run intensifies.
Johnson-Johnson stated that its Janssen Pharmaceutica unit would provide the British government with its candidate known as Ad26. COV2. S with an initial sale of 30 million non-profit doses for emergency use in the event of a pandemic.
The early acquisition agreement will also offer an option for an additional acquisition of up to 22 million doses, he said.
In a separate statement, Novavax said the UK would acquire 60 million doses of its coronavirus vaccine candidate, NVX-CoV2373, for a phase 3 trial.
With six agreements to date, Britain and the United States are leading the global race toward agreements with vaccine drug brands as the pandemic continues.
The most recent agreements bring the total number of guaranteed doses in the UK to 362 million for a population of millions.
J-J said he had also agreed to work with the UK government on a global trial 3 to explore the two-dose scheme of his candidate vaccine.
It will be executed in parallel with the testing phase of the single-dose program.
No vaccine has been shown to be effective so far, more than 20 applicants are in clinical trials.
(Report through Alistair Smout and Josephine Mason; edited through Jan Harvey and Jason Neely)